Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$16.2M | -$7.22M | -$6.92M | -$12.7M | -$60.8M | -$126M | -$161M | -$104M | -$83.9M | -$59.1M |
| Net income | -$2.97M | -$6.29M | -$8.96M | -$17.3M | -$59.5M | -$126M | -$157M | -$98.8M | -$80.0M | -$57.4M |
| EPS (diluted) | -$0.26 | -$0.52 | -$0.71 | -$2.74 | -$3.81 | -$7.16 | -$5.30 | -$3.28 | -$2.65 | -$1.45 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.1M | -$6.47M | -$6.00M | -$10.5M | -$27.8M | -$91.9M | -$104M | -$51.7M | -$51.8M | -$45.8M |
| Capital expenditures | $562K | $49.7K | $12.4K | $84.8M | $182M | — | — | — | — | — |
| Free cash flow | -$13.7M | -$6.52M | -$6.01M | -$95.3M | -$210M | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.50M | $1.71M | $2.24M | $9.22M | $2.50M | $44.4M | $5.40M | $4.09M | $3.86M | $3.50M |
| Total assets | $10.2M | $2.84M | $3.05M | $10.2M | $118M | $223M | $153M | $97.6M | $45.8M | $94.0M |
| Total liabilities | $3.20M | $1.38M | $8.56M | $2.61M | $12.6M | $15.1M | $12.5M | $12.2M | $10.3M | $7.49M |
| Shareholders' equity | $7.04M | $1.46M | -$5.51M | $116M | $106M | $208M | $140M | $85.4M | $35.5M | $86.5M |
| Retained earnings | -$79.1M | -$85.4M | -$94.3M | -$112M | -$179M | -$305M | -$462M | -$561M | -$641M | -$698M |
| Shares (wtd avg diluted) | 12.0M | 12.5M | 12.5M | 9.74M | 16.3M | 17.6M | 29.6M | 30.1M | 30.2M | 39.5M |
Every figure is extracted from RELMADA THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.